Menopause and Aging

Yen & Jaffe's Reproductive Endocrinology

Volumn , Issue , 2009, Pages 325-355

  Lobo, Rogerio A ^a  

^a REI Fellowship Program ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649459663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4907-4.00014-0     Document Type: Chapter

References (390)

1. U.S.Bureau of the Census Current population reports: Projections of the population of the United States 1977 to 2050 1993, U.S. Government Printing Office, Washington, DC.
2. Willett W., Stampfer M.J., Bain C., et al. Cigarette smoking, relative weight and menopause. Am J Epidemiol 1983, 117:651-658.
3. Luoto R., Laprio J., Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994, 139:64-76.
4. Cooper G.S., Sandler D.P. Age at natural menopause and mortality. Ann Epidemiol 1998, 8:229-235.
5. Wise A.M., Krajnak K.M., Kashon M.L. Menopause: the aging of multiple pacemakers. Science 1996, 273:67-70.
6. Snowdon D.A., Kane R.L., Besson W.L., et al. Is early natural menopause a biologic marker of health and aging?. Am J Public Health 1989, 79:709-714.
7. Stanford L., Hartge P., Brinton L.A., et al. Factors influencing the age at natural menopause. J Chron Dis 1987, 40:995-1002.
8. van Noord P.A., Dubas J.S., Dorland M., et al. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997, 68:95-102.
9. Greendale G., Hogan P., Kritz-Silverstain D., et al. Age at menopause in women participating in the postmenopausal estrogen/progestins interventions (PEPI) trial: an example of bias introduced by selection criteria. Menopause 1995, 2:27-34.
10. Scragg R.F.R. Menopause and reproductive span in rural Nulgini. Proc Ann Symp Papua New Guinea Med Soc 1973, 126-144.
11. Baird D.D., Trlavsky F.A., Anderson J.J.B. Do vegetarians have earlier menopause?. Am J Epidemiol 1988, 128:907-908.
12. Bromberger J.T., Matthews K.A., Kuller L.H., et al. Prospective study of the determinants of age at menopause. Am J Epidemiol 1997, 145:124-133.
13. Alvarado G., Rivera R., Ruix R., et al. Characteristicas del; patron de sangrado menstrual; en un grupo de mujeres normales de Durango. Ginecol Obstet Mexico 1998, 56:127-133.
14. Chompootweep S., Tankeyoon M., Yamarat K., et al. The menstrual age and climacteric complaints in Thai women in Bangkok. Maturitas 1993, 17:63-71.
15. Beyene Y. Cultural significance and physiological manifestations of menopause, a bicultural analysis. Cultural Med Psych 1986, 10:47-71.
16. Ramoso-Jalbuena J. Climacteric Filipino women: A preliminary survey in the Philippines. Maturitas 1994, 19:183-190.
17. Beall C.M. Ages at menopause and menarche in a high altitude Himalayan population. Ann Hum Biol 1983, 10:365-370.
18. Gonzalez G.F., Villena A. Age at menopause in central Andean Peruvian women. Menopause 1997, 4:32-38.
19. de Bruin J.P., Bovenhuis H., van Noord P.A., et al. The role of genetic factors in age at natural menopause. Hum Reprod 2001, 16:2014-2018.
20. de Moraes M., Jones G.S. Premature ovarian failure. Fertil Steril 1967, 18:440.
21. Alper M.M., Garner P.R., Cher B., et al. Premature ovarian failure. J Reprod Med 1986, 31:699-708.
22. Aiman J., Smentek C. Premature ovarian failure. Obstet Gynecol 1985, 66:9-14.
23. Coulam C.B., Adamson S.C., Annegers J.F. Incidence of premature ovarian failure. Obstet Gynecol 1986, 67:604-606.
24. Faddy M.J., Gosden R.J., Gougeon A., et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992, 7:1342-1346.
25. Gougeon A., Ecochard R., Thalabard J.C. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non growing and early growing follicles in aging women. Biol Reprod 1994, 50:653-663.
26. Rosen G.E., Kaplan B., Lobo R.A. Menstrual function and hirsutism in patients with gonadal dysgenesis. Obstet Gynecol 1988, 71:677-680.
27. Rebar R.W., Erickson G.F., Coulam C.B. Premature ovarian failure. Pathology of Infertility 1987, 123-141. Thieme Medical Publishers, New York. B. Gondos, D. Riddick (Eds.).
28. Aiman J., Smentek C. Premature ovarian failure. Obstet Gynecol 1985, 66:9-14.
29. Kinch R.A.H., Plunkett E.R., Smout M.S., Carr D.H. Primary ovarian failure: a clinicopathological and cytogenetic study. Am J Obstet Gynecol 1965, 91:630-644.
30. Krauss C.M., Turksoy R.N., Atkins L., et al. Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome. N Engl J Med 1987, 317:125-131.
31. Coulam C.B., Stringfellow S.S., Hoefnagel D. Evidence for a genetic factor in the etiology of premature ovarian failure. Fertil Steril 1983, 40:693-695.
32. Mattison D.R., Evans M.I., Schwimmer W.B., et al. Familial premature ovarian failure. Am J Hum Genet 1984, 36:1341-1348.
33. Starup J., Philip J., Sele V. Oestrogen treatment and subsequent pregnancy in two patients with severe hypergonadotropic ovarian failure. Acta Endocriol (Copenhagen) 1978, 89:149-157.
34. Aittomaki K., Lucena J.L.D., Pakarinen P., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82:959-968.
35. Jacobs P.A. Fragile X syndrome. J Med Genet 1991, 28:809-810.
36. Turner G., Robinson H., Wake S., Martin S. Dizygous twinning and premature menopause in fragile X syndrome. Lancet 1994, 344:1500.
37. Conway G.S., Hettiarachchi S., Murray A. Jacobs PA. Fragile X permutations in familial premature ovarian failure. Lancet 1995, 346:309-310.
38. De Baere E., Dixon M.J., Small K.W., et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype-phenotype correlation. Hum Mol Genet 2001, 15:1591-1600.
39. Harper P.S., Dyken P.R. Early onset dystrophic myotonia. Lancet 1972, 2:53-55.
40. Hoefnagel D., Wurster-Hili D., Child E.L. Ovarian failure in galactosemia. Lancet 1979, 2:1197.
41. Kaufman F.R., Kogut M.D., Donnell G.N., et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981, 304:994-998.
42. Bigleri E.G., Herron M.A., Brust N. 17-Hydroxylation deficiency in man. J Clin Invest 1996, 45:1946-1954.
43. Goldsmith O., Solomon D.H., Horton R. Hypogonadism and mineral-corticoid excess. The 17-hydroxylase deficiency syndrome. N Engl J Med 1967, 277:673-677.
44. Mallin S.R. Congenital adrenal hyperplasia secondary to 17-hydroxylase deficiency: two sisters with amenorrhea, hypokalemia, hypertension and cystic ovaries. Ann Intern Med 1969, 70:69-75.
45. LaBarbera A.R., Miller M.M., Ober C., Rebar R.W. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988, 16:115-122.
46. Bjorses P., Aaltonen J., Horelli-Kuitunen N., et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998, 7:1547-1553.
47. Healy D.L., Bacher J., Hodgen G.D. Thymic regulation of primate fetal ovarian-adrenal differentiation. Biol Reprod 1985, 32:1127-1133.
48. Rabinowe S.L., Berger M.J., Welch W.R., et al. Lymphocyte dysfunction in autoimmune oophoritis: resumption of menses with corticosteroids. Am J Obstet Gynecol 1986, 81:348.
49. Bateman B.G., Nunley W.C., Kitchin J.D. Reversal of apparent premature ovarian failure in a patient with myasthenia gravis. Fertil Steril 1983, 39:108-110.
50. Coulam C.B., Kempers R.D., Randall R.V. Premature ovarian failure: evidence for the autoimmune mechanism. Fertil Steril 1981, 36:238-240.
51. Lucky A.W., Rebar R.W., Blizzard R.M., Goren E.M. Pubertal progression in the presence of elevated serum gonadotropins in girls with multiple endocrine deficiencies. J Clin Endocrinol Metab 1977, 45:673-678.
52. Hoek A., Shoemaker J., Drexhage H.A. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997, 18:107-134.
53. Arif S., Vallian S., Farazneh F., et al. Identification of 3 beta-hydroxysteroid dehydrogenase as novel target of steroid-producing cell autoantibodies: association of autoantibodies with endocrine autoimmune disease. J Clin Endocrinol Metab 1996, 81:4439-4445.
54. Rebar R.W. Premature ovarian failure. Treatment of the Postmenopausal Woman 2007, 99-109. Academic Press, New York. 3rd ed. R.A. Lobo (Ed.).
55. Chen S., Sawicka J., Betterle C., et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinal Metab 1996, 81:1871-1876.
56. Silva de Sa M.F., Matthews M.J., Rebar R.W. Altered forms of immunoreactive urinary FSH and LH in premature ovarian failure. Infertility 1988, 11:1-11.
57. Sluss P.M., Schneyer A.L. Low molecular weight follicle-stimulating hormone receptor binding inhibitor in sera from premature ovarian failure patients. J Clin Endocrinol Metab 1992, 74:1242-1246.
58. Morrison J.C., Givens J.R., Wiser W.L., Fisk S.A. Mumps oophoritis: a cause of premature menopause. Fertil Steril 1975, 26:655-659.
59. Siris E.S., Leventhal B.G., Vaitukaitis J.L. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976, 294:1143-1146.
60. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980, 53:271-278.
61. Ray G.R., Trueblood H.W., Enright L.P., et al. Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin's disease. Radiology 1970, 96:175-180.
62. Stillman R.J., Schiff I., Schinfeld J. Reproductive and gonadal function in the female after therapy for childhood malignancy. Obstet Gynecol Surv 1982, 37:385-393.
63. Whitheead E., Shalet S.M., Blackledge G., et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983, 52:988-993.
64. Damewood M.D., Grochow L.B. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986, 45:443-459.
65. Rebar R.W. Premature ovarian failure. Menopause-Biology and Pathobiology 2000, 135-146. Academic Press, New York. R.A. Lobo, J. Kelsey, R. Marcus (Eds.).
66. Alper M.M., Jolly E.E., Garner P.B. Pregnancies after premature ovarian failure. Obstet Gynecol 1986, 67:595-625.
67. Ledger W.L., Thomas E.J., Browning D., et al. Suppression of gonadotropin secretion does not reverse premature ovarian failure. J Obstet Gynecol 1989, 96:196-199.
68. Atsma F., Bartelink M.L., Grobbee D.E., et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13(2):265-279. (review).
69. Soules M.R., Sherman S., Parrott E., et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001, 76:874-878.
70. Erickson G.F. An analysis of follicle development and ovum maturation. Semin Reprod Endocrinol 1986, 4:233-254.
71. Faddy M.J., Gosden R.G., Gougeon A., et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992, 7:1342-1346.
72. Rannevik G., Jeppsson S., Johnell O., et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones SHBG and bone mineral density. Maturitas 1995, 21:103-113.
73. Klein N.A., Illingworth P.J., Groome N.P., et al. Decreased inhibin B secretion is associated with the menotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996, 81:2742-2745.
74. Welt C.K., McNicholl D.J., Taylor A.E., Hall J.E. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999, 84:105-111.
75. Klein N.A., Battaglia D.E., Clifton D.K., et al. The gonadotropin secretion pattern in normal women of advanced reproductive age in relation to the monotropic FSH rise. J Soc Gynecol Investig 1996, 3:27-32.
76. Hughes E.G., Robertson D.M., Handelsman D.J., et al. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome. J Clin Endocrinol Metab 1990, 70:358-364.
77. Licciardi F.L., Liu H.C., Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995, 64:991-994.
78. Scott R.T., Leonardi M.R., Hofmann G.E., et al. A prospective evaluation of clomiphene citrate challenge test screening of the general infertility population. Obstet Gynecol 1993, 82:539-574.
79. Xiao S., Robertson D.M., Findlay J.K. Effects of activin and follicle-stimulating hormone (FSH) suppression protein/follistatin on FSH receptors and differentiation of cultured rat granulosa cells. Endocrinology 1992, 131:1009-1016.
80. Reame N.E., Wyman T.L., Phillips D.J., et al. Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating of hormone of aging cyclic women. J Clin Endocrinol Metab 1998, 83:3302-3307.
81. Erickson G.F., Kokka S., Rivier C. Activin causes premature superovulation. Endocrinology 1995, 136:4804-4813.
82. Yen S.S.C. The biology of menopause. J Reprod Med 1977, 18:287.
83. Dowsett M., Cantwel B., Lal A., et al. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 1988, 66:672-677.
84. Andreyko J.L., Monroe S.E., Marshall L.A., et al. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix). J Clin Endocrinol Metab 1992, 74:399-405.
85. Couzinet B., Meduri G., Lecce M.G., et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001, 86:5060-5066.
86. Vermuelen A. Dehydroepiandrosterone and aging. Ann NY Acad Sci 1995, 774:121-127.
87. Lasley B.L., Santoro N., Randolf J.F., et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab 2002, 87:3760-3767.
88. Zumoff B., Strain G.W., Miller L.K., et al. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995, 80:1429-1430.
89. Burger H.G., Dudley E.C., Cui J., et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000, 85:2832-2838.
90. Rance N.E., Young W.S., McMullen N.T. Topography of neurons expressing luteinizing hormone-releasing hormone gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol 1994, 339:573-586.
91. Rance N.E., Uswandi S.V. Gonadotropin-releasing hormone gene expression is increased in the medial basal hypothalamus of postmenopausal women. J Clin Endocrinol Metab 1996, 81:3540-3546.
92. Arisawa M., De Palatis L., Ho R., et al. Stimulatory role of substance P on gonadotropin release in ovariectomized rats. Neuroendocrinology 1990, 51:523-529.
93. Rance N.E., Young W.S. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991, 128:2239-2247.
94. Abel T.W., Voytko M.L., Rance N.E. The effects of hormone replacement therapy on hypothalamic neuropeptide gene expression in a primate model of menopause. J Clin Endocrinol Metab 1999, 84:2111-2118.
95. Wise P.M., Krajnak K.M., Kashon M.L. Menopause: the aging of multiple pacemakers. Science 1996, 273:67-70.
96. Wise P.M., Scarbrough K., Lloyd J., et al. Neuroendocrine concomitants of reproductive aging. Exp Gerontol 1994, 29:275-283.
97. Wise P.M. Menopause and the brain. Sci Am (Special issue: Women's Health-A Lifelong Guide) 1998, 9:79-81.
98. Veldhuis J.D., Iranmanesh A., Johnson M.L., Lizarralde G. Twenty-four hour rhythms in plasma concentrations of adrenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J Clin Endocrinol Metab 1990, 71:1616-1623.
99. Reame N., Luckas J., Ansbacher R., et al. The hypothalamic GnRH pulse generator is altered in ovulatory, premenopausal women: evidence from 24 hr pulsatile LH studies. Fertil Steril 2002, 255:S97.
100. Yen S.S.C. Neuroendocrine rhythms of gonadotropin secretion in women. Biorhythms and Human Reproduction 1977, 219-238. John Wiley & Sons, New York. M. Ferin, F. Halberg, R.M. Richart, R.L. aVande Wiele (Eds.).
101. Jones K.P., Walker L.C., Anderson D. Depletion of ovarian follicles. Biol Reprod, 2007, 77:247-251.
102. van Disseldorp J., Faddy M.J., Themmen A.P., et al. Relationship of serum anti-mullerian hormone concentration to age of menopause. J Clin Endocrinol Metab 2008, 93(6):2129-2134.
103. Hehenkamp W.J., Looman C.W., Themmen A.P., et al. Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006, 91(10):4057-4063.
104. MacLusky N., Naftolin F. Sexual differentiation of central nervous system. Science 1981, 211:1294-1302.
105. Toran-Allerand C.D., Guan X., MacLusky N.J., et al. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 2002, 22:8391-8401.
106. Shughrue P., Lane M., Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997, 388:507-525.
107. Laflamme N., Nappi R., Drolet G., et al. Expression and neuropeptidergic characterization of estrogen receptor (ER alpha and beta) throughout the rat brain: anatomical evidence of district role of each subtype. J Neurobiol 1998, 36:357-378.
108. Henderson V.W. Estrogen, cognition and a woman's risk of Alzheimer's disease. Am J Med 1997, 103:11-18.
109. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
110. Feldman B.M., Voda A.M., Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985, 8:261-268.
111. Oldenhave A., Jaszmann L.J., Haspels A.A., Everaerd W.T. Impact of climateric on well-being. A study based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993, 168:772.
112. Gold E.B., Sternfeld B., Kelsey J.L., et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000, 152:463.
113. Meldrum D.R., Tataryn I.V., Frumar A.M., et al. Gonadotropins, estrogens, and adrenal steroids during the menopausal hot flash. J Clin Endocrinol Metab 1980, 50:685-689.
114. Genazzani A.R., Petraglia F., Facchinetti F., et al. Increase of proopiomelanocortin-related peptides during subjective menopausal flushes. Am J Obstet Gynecol 1984, 149:775-779.
115. Freedman R.R. Menopausal hot flashes. Treatment of the Postmenopausal Woman 2007, 187-198. Academic Press, New York. 3rd ed. R.A. Lobo (Ed.).
116. Erlik Y., Tataryn I.V., Meldrum D.R., et al. Association of waking episodes with menopausal hot flushes. JAMA 1981, 245:1741-1744.
117. Shaver J., Giblin E., Lentz M., Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988, 11:556-561.
118. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
119. Thomson J., Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. Br Med J 1977, 2:1317-1319.
120. Schiff I., Regestein Q., Tulchinsky D., Ryan K.J. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979, 242:2405-2407.
121. Schneider M.A., Brotherton P.L., Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust 1977, 2:162-163.
122. Fedor-Freybergh P. The influence of oestrogens on the well being and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl 1977, 64:1-99.
123. Sherwin R.B., Gelfand M.M. Sex steroids and affect in the surgical menopause: double-blind cross-over study. Psychoneuroendocrinology 1985, 10:325-335.
124. Montgomery J.C., Appleby L., Brincat M., et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987, 1:297-299.
125. Sherwin B.B. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affective Disord 1988, 14:177-187.
126. Ditkoff E.C., Crary W.G., Cristo M., Lobo R.A. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991, 78:991-995.
127. Best N.R., Rees M.P., Barlow D.H., Cowen P.J. Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. Psychoneuroendocrinology 1972, 17:87-93.
128. Klaiber E.L., Broverman D.M., Vogel W., Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979, 36:550-554.
129. Zweifel J.E. O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997, 22:189-212.
130. Sherwin B.B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991, 72:336-343.
131. Holst J., Backstrom T., Hammarback S., von Schoultz B. Progestogen addition during oestrogen replacement therapy: Effects on vasomotor symptoms and mood. Maturitas 1989, 11:13-20.
132. Klaiber E.L., Broverman D.M., Vogel W., et al. Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology 1996, 21:575-592.
133. Jacobs D.M., Tang M.X., Stern Y., et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998, 50:368-373.
134. Maki P.M., Zonderman A.B., Resnick S.M. Enhanced verbal memory in nondemented elderly estrogen users. Am J Psychiatry 2001, 158:227-233.
135. Maki P.M., Resnick S.M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000, 21:373-383.
136. Resnick S.M., Makii P.M., Golski S., et al. Effects of estrogen replacement therapy on PET cerebrala blood flow and neuropsychological performance. Hormone Behav 1998, 34:171-182.
137. Shaywitz S.E., Shaywitz B.A., Pugh K.R., et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory task. JAMA 1999, 281:1197-1202.
138. Toran-Allerand C.D., Miranda R.C., Bentham W.D.L., et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci 1992, 89:4668-4672.
139. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
140. LeBlanc E.S., Janoowsky J., Chan B.K., Nelson H.D. Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA 2001, 285:1489-1499.
141. Heyman A., Wilkinson W.E., Stafford J.A., et al. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984, 15:335-341.
142. Amaducci L.A., Henderson A.S., Creasey H., et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986, 36:922-931.
143. Broe G.A., Henerson A.S., Creasy H., et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990, 40:1698-1707.
144. Graves A.B., White E., Koepsell T.D., et al. A case-control study of Alzheimer's disease. Ann Neurol 1990, 28:766-774.
145. Brenner D.E., Kukull W.A., Stergachis A., et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994, 140:262-267.
146. Henderson V.W., Paganini-Hill A., Emanuel C.K., et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994, 51:896-900.
147. Paganini-Hill A., Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256-261.
148. Mortel K.F., Meyer J.S. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995, 7:334-337.
149. Baldereschi M., Di Carlo A., Lepore V., et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998, 50:996-1002.
150. Wang S.C., Rocca W.A., Petersen R.C., et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1995, 52:965-970.
151. Slooter A.J., Bronzova J., Witteman J.C., et al. Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry 1999, 67:779-781.
152. Tang M.-X., Jacobs D., Stern Y., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429-432.
153. Kawas C., Resnick S., Morrison A., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal study of aging. Neurology 1997, 48:1517-1521.
154. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998, 279:688-695.
155. LeBlanc E.S., Janowsky J., Chan B.K., Nelson H.D. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001, 285:1489-1499.
156. Harwood D.G., Barker W.W., Loewenstein D.A., et al. A cross-ethnic analysis or risk factors for AD in white Hispanics and white non-Hispanics. Neurology 1999, 52:551-556.
157. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996, 156:2213-2217.
158. Mulnard R.A., Cotman C.W., Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000, 283:1007-1015.
159. Brincat M., Moniz C.J., Studd J.W.W., et al. Sex hormones and skin collagen content in postmenopausal women. Br Med J 1983, 287:1337-1338.
160. Brincat M., Kabalan S., Studd J.W.W., et al. A study of the relationship of skin collagen content, skin thickness and bone mass in the postmenopausal woman. Obstet Gynecol 1987, 70:840-845.
161. Punnonen R. Effect of castration and peroral therapy on skin. Acta Obstet Gynaecol Scand Suppl 1973, 21:1-4.
162. Brincat M., Moniz C.J., Studd J.W.W., et al. Long term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985, 92:256-259.
163. Castelo-Branco C., Duran M., Gonzalez-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992, 15:113-119.
164. Dunn L.B., Damesyn M., Moore A.A., et al. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANESI). Arch Dermatol 1997, 133:339-342.
165. Varila E., Rantala I., Ikarinem A., et al. The effect of topical oestriol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995, 102:985-989.
166. Shahrad P., Marks R.A. Pharmacological effect of oestrone on human epidermis. Br J Dermatol 1977, 97:383-386.
167. Versi E., Caradozo L.D., Brincat M., et al. Correlation of urethral physiology and skin collagen in postmenopausal women. Br J Obstet Gynaecol 1988, 95:147-152.
168. Falconer C., Ekman Orderberg G., Ulmasten U., et al. Changes in paraurethral connective tissue at menopause are counteracted by estrogen. Maturitas 1996, 24:197-204.
169. Samuelsson E.C., Victor F.T., Svardsudd K.F. Five-year incidence and remission rates of female urinary incontinence in a Swedish population less than 65 years old. Am J Obstet Gynecol 2000, 183:568-574.
170. Barlow D.H., Samsioe G., van Geelen J.M. A study of European women's experience of the problems of urogenital ageing and its management. Maturitas 1997, 27:239-247.
171. Diokno A.C., Brock B.M., Brown M.B., Herzog A.R. Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol 1986, 136:1022-1025.
172. Hilton P., Tweddel A.L., Mayne C. Oral and intravaginal oestrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. Int Urogynecol J 1990, 12:80-86.
173. Hilton P., Stanton S.L. The use of intravaginal estrogen cream in genuine stress incontinence: a double blind clinical trial. Urol Int 1978, 33:136-143.
174. Wilson P.D., Paragher B., Butler B., et al. Treatment with oral piperalzine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987, 94:568-574.
175. Elia G., Bergman A. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv 1993, 48:509-517.
176. Fantl J.A., Bump R.C., Robinson D., et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence: The Continence Program for Women Research Group. Obstet Gynecol 1996, 88:745-749.
177. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993, 329:753-756.
178. Heimer G., Samsioe G. Effects of vaginally delivered estrogens. Acta Obset Gynecol Scand 1996, (Suppl):1-2.
179. Ashcroft G.S., Dodsworth J., van Boxtel E., et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels. Nat Med 1997, 3:1209-1215.
180. Ashcroft G.S., Greenwell-Wild T., Horan M.A., et al. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol 1997, 155:1137-1146.
181. Dennerstein L., Dudley E.C., Hopper J.L., et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000, 96:351-358.
182. Versi E., Harvey M.A., Cardozo L., et al. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct 2001, 12:107-110.
183. Stenburg A., Heimer G., Ulmsten U., Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996, 24:31-36.
184. Semmens J.P., Tsai C.C., Semmens E.F., Loadholt C.B. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol 1985, 66:15-18.
185. Riggs B.L., Wahmer H.W., Melton L., et al. Rates of bone loss in the appendicular and axial skeletons of women: evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986, 77:1487-1491.
186. Slemenda C. Huise, Longcope C, Johnston CC. Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 1987, 80:1261-1269.
187. Melton L.J., Chrischilles E.A., Cooper C., et al. Perspective: how many women have osteoporosis?. J Bone Miner Res 1992, 7:1005-1010.
188. Cooper C., Campion G., Melton L.J. Hip fractures in the elderly: a world-wide projection. Obsteoporosis Int 1992, 2:285-289.
189. Ray N.F., Chan J.K., Thamer M., Melton L.J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:24-35.
190. Riggs B.L., Melton L.J. Involutional osteoporosis. N Engl J Med 1986, 314:1676-1686.
191. Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19:717-797.
192. Kasperk C.H., Wergedak J.E., Farley J.R., et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989, 124:1576-1578.
193. Wakley G.K., Schutter H.D., Hannon K.S., Turner R.T. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res 1991, 6:325-330.
194. Ericksen E.F., Colvard D.S., Berg N.J., et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988, 241:84-86.
195. Komm B.S., Terpening C.M., Benz D.J., et al. Estrogen binding receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-84.
196. Oursler M.J., Osdoby P., Pyfferoen J., et al. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci U S A 1991, 88:6613-6617.
197. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci U S A 1994, 91:5227-5231.
198. Braidman I., Baris C., Wood L., et al. Preliminary evidence for impaired estrogen receptor-a protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone 2000, 26:423-427.
199. Tomkinson A., Gevevers E.F., Wit J.M., et al. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998, 13:1243-1250.
200. Bord S., Horner A., Beavan S., Compston J. Estrogen receptors a and b are differentially expressed in developing human bone. Endocrinology 2001, 86:2309-2314.
201. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
202. Pacifici R. Estrogen, cytokines, and pathogenesis of post-menopausal osteoporosis. J Bone Miner Res 1996, 11:1043-1051.
203. Riggs B.L. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000, 106:1203-1204.
204. Oursler M.J., Cortese C., Keeting P.E., et al. Modulation of transforming growth factorβ production in normal human
205. Suda T., Takahashi N., Udagawa N., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
206. Hofbauer L.C., Khosla S., Dunstan C.R., et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
207. Riggs B.L. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000, 106:1203-1204.
208. Riggs B.L., Khosla S., Melton J.L. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
209. Riggs B.L., Khosla S., Melton J.L. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998, 13:763-773.
210. Frost H.M. The role of changes in mechanical usage set points in the pathogenesis of osteoporosis. J Bone Miner Res 1992, 7:253-261.
211. Frost H.M. On rho, a marrow mediator, and estrogen: their roles in bone strength and "mass" in human females, osteopenias, and osteoporosis-insights from a new paradigm. J Bone Miner Metab 1998, 16:113-123.
212. Frost H.M. Perspective on the estrogen-bone relationship and postmenopausal bone loss. J Bone Miner Res 1999, 14:1473-1477.
213. Nguyen T.V., Blangero J., Eisman J.A. Genetic epidemiological approaches to the search for osteoporosis genes. J Bone Miner Res 2000, 15:392-401.
214. Smith E.P., Boyd J., Frank G.R., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
215. Morishima A., Grumbach M.M., Simpson E.R., et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80:3689-3698.
216. Carani C., Quin K., Simoni M., et al. Effect testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997, 337:91-95.
217. Bilezikian J.P., Morishima A., Bell J., Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998, 339:599-603.
218. van Kuijk C., Genant H.K. Detection of osteopenia. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects 1999, 287-292. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. R.A. Lobo (Ed.).
219. Khosla S., Riggs B.L., Atkinson E.J., et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006, 21:124-131.
220. Eastell R., Hannon R.A. Biochemical markers of bone turnover. Treatment of the Postmenopausal Woman Basic and Clinical Aspects 2007, p, 337-350. Elsevier Academic Press, St. Louis. 3rd ed. R.A. Lobo (Ed.).
221. Lobo R.A., Whitehead M. Is low-dose hormone replacement for postmenopausal women efficacious and desirable?. Climacteric 2001, 4:110-119. 2001.
222. Lindsay R., Gallagher J.C., Kooper M., Pickar J.H. Effect of lower doses of conjugated equine estrogen with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002, 287:2668-2676.
223. Riis B.J., Lehmann H.J., Christiansen C. Northindrone acetate in combination with estrogen: effects on the skeleton and other organs. Am J Obstet Gynecol 2002, 187:1101-1116.
224. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999, 282:637-645.
225. Geusens P., Dequeker J., Gielen J., Schot L.P.C. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991, 13:155-162.
226. Bjarnason N.H., Bjarnason K., Haarbo J., et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996, 81:2419-2422.
227. Adami S., Zamberlan N., Mian M., et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994, 25:75-82.
228. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998, 280:2077-2082.
229. Overgaard K., Hansen M.A., Jensen S.B. Effects of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 1992, 305:556-561.
230. Rico H., Hernandez E.R., Revilla M., Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rates in postmenopausal crush fracture syndrome. Bone Miner 1992, 16:131-138.
231. Riggs B.L., Hodgson S.F., O'Fallon W.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
232. Pak C.Y.C., Sakhaee K., Adams-Huet B., et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995, 123:401-408.
233. Heaney R.P. Fluoride and osteoporosis. Ann Intern Med 1994, 120:689-690.
234. Lindsay R., Nieves J., Formica C., et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
235. Dawson-Hughes B., Harris S.S., Krall E.A., Dalla G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
236. Paganini-Hill A., Chao A., Ross R.K., Henderson B.E. Exercise and other factors in the prevention of hip fracture: the leisure world study. Epidemiology 1991, 2:16-25.
237. Tinetti M.E., Baker D.I., McAvay G., et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994, 331:821-827.
238. Kannel W.B., Hjortland M.C., McNamara P.M., Gordon T. Menopause and the risk of cardiovascular disease. The Framingham study. Ann Intern Med 1976, 85:447-452.
239. Cummings S.R., Black D.M., Rubin S.M. Lifetime risks of hip, colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989, 14:2445-2448.
240. Rosenberg L., Hennekens C.H., Rosner B. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981, 139:47-51.
241. Lobo R.A. Surgical menopause and cardiovascular risks. Menopause 2007, 14(3):562-566.
242. Parker W.H., Broder M.S., Liu Z., et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005, 106(2):219-226.
243. Matthews K.A., Meilahn E., Kuller L.H., et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641-646.
244. Notelovitz M., Ware M. Coagulation risks with postmenopausal oestrogen therapy. Progress in Obstetrics and Gynecology 1982, Churchill Livingston, Edinburgh. J. Studd (Ed.).
245. Gilligan D.M., Quyyumi A.A., Cannon R.O. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551.
246. Collins P., Rosano G.M.C., Sarrel P.M., et al. Estradiol-17b attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995, 92:24-30.
247. McCrohon J.A., Walters W.A., Robinson J.T., et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997, 29:1437-1444.
248. Pines A., Fisman E.Z., Drory Y., et al. Menopause-induced changes in Doppler-derived parameters of aortic flow in healthy women. Am J Cardiol 1992, 69:1104-1106.
249. Ganger K.F., Vyas S., Whitehead M., et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991, 338:839-842.
250. Proudler A.J., Hasib Ahmed A.J., Crook D., et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995, 346:89-90.
251. Rosano G.M.C., Caixeta A.M., Chierchia S.L., et al. Acute anti-ischemic effect of estradiol-17b in postmenopausal women with coronary artery disease. Circulation 1997, 96:2837-2841.
252. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from American Heart Association. Circulation 2001, 104:499-503.
253. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
254. Mendelsohn M.E. Nongenomic, estrogen receptor-mediated activation of endothelial nitric oxide synthase. How does it work? What does it mean?. Circ Res 2000, 87:956-960.
255. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613.
256. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522-529.
257. Clarke S.C., Kelleher J., Lloyd-Jones H., et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002, 109:1056-1062.
258. Reis S.E., Gloth S.T., Blumenthal R.S., et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
259. Campisi R., Nathan L., Pampaloni M.H., et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation 2002, 105:425-430.
260. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, review, 308(5728):1583-1587.
261. Post W.S., Goldschmidt-Clermont P.J. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999, 43:985-991.
262. Umetani M., Domoto H., Gormley A.K., et al. 27-Hydroxycholesterol as an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007, 13(10):1185-1192.
263. Lindheim S.R., Presser S.C., Ditkoff E.C., et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993, 60:664-667.
264. Lindheim S.R., Legro R.S., Bernstein L., et al. Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 1992, 167:1831-1836.
265. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
266. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002, 288:49-57.
267. Alexander K.P., Newby L.K., Hellkamp A.S., et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow up. J Am Coll Cardiol 2001, 38:1-7.
268. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med 2001, 135:1-8.
269. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
270. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998, 83:721-726.
271. Adams M.R., Register T.C., Golden D.L., et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:217-221.
272. Clarkson T.B., Anthony M.S., Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001, 86:41-47.
273. Williams J.K., Anthony M.S., Honore E.K., et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995, 15:827-836.
274. Clarkson T.B. The new conundrum: do estrogens have any cardiovascular benefits?. Int J Fertil 2002, 47:61-68.
275. Herrington D.M., Vittinghoff E., Lin F. Statin therapy, cardiovascular events and total mortality in the heart and estrogen/progestin replacement study (HERS). Circulation 2002, 105:2962-2967.
276. Shlipak M., Angeja B.G., Go A.S., et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001, 104:2300-2304.
277. Lobo R.A. Evaluation of cardiovascular event rates with hormone therapy in healthy postmenopausal women: results from four large clinical trials. Arch Intern Med 2004, 164:48-84.
278. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006, 166:357-365.
279. Salpeter S.R., Walsh J.M., Greyer E., et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006, 21:363-366.
280. Salpeter S.R., Walsh J.M., Greyber E., et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004 (review), 19(7):791-804.
281. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591-2602.
282. Prentice R.L., Langer R., Stefanick M.L., et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005, 162(5):404-414.
283. Prentice R.L., Langer R.D., Stefanick M.L., et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006, 163(7):589-599.
284. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA 2007, 297(13):1465-1477.
285. Lobo R.A. Menopause and stroke and the effects of hormonal therapy. Climacteric Suppl 2007, 2:27-31. review.
286. Rosendaal F.R., Vessey M., Rumley A., et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002, 116(4):851-854.
287. Canonico M., Oger E., Plu-Bureau, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007, 115(7):840-845.
288. Scarabin P.Y., Oger E., Plu-Bureau, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362(9382):428-432.
289. Lobo R.A. What is the effect of estrogen on blood pressure after menopause?. Menopause 2006, 13(3):331-333.
290. Collins J.A., Blake J.M., Crosignani P.G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005, 11(6):545-560.
291. Anderson G.L., Chlebowski R.T., Rossouw J.E. Prior hormone therapy and breast cancer risk in the women's health initiative randomized trial of estrogen and progestin. Maturitas 2006, 55:107-115.
292. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295(14):1647-1657.
293. Chen W.Y., Manson J.E., Hankinson S.E., et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006, 166:1027-1032.
294. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362(9382):419-427. Million Women Study Collaborators.
295. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008, 107(1):103-111.
296. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356(16):1670-1674.
297. Heiss G., Wallace R. Anderson al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008, 299(9):1036-1045.
298. International Menopause Society Climacteric 2007, 2007(10):181-194.
299. Utian W.H., Archer D.F., Bachmann G.A., et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008, 15(4 pt 1):584-602.
300. Lobo R.A., Bélisle S., Creasman W.T., et al. Should symptomatic menopausal women be offered hormone therapy?. Med Gen Med 2006, 8(3):40.
301. American Association of Clinical Endocrinologists. Available at: . http://www.ace.com/pub.
302. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 151:75-78.
303. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996, 87:6-12.
304. Grodstein F., Stampfer M.J., Colditz G.A., et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775.
305. Woodruff J.D., Pickar J.H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994, 170:1213-1223.
306. PEPI Trial Writing Group Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996, 275:370-375.
307. Collins J.A., Allen I., Donner A., Adams O. Oestrogen use and survival in endometrial cancer. Lancet 1980, 2:961-963.
308. Schwartzbaum J.A., Hulka B.S., Fowler W.C., et al. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987, 126:851-860.
309. Lacey J.V., Mink P.J., Lubin J.H., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002, 288:368-369.
310. Riman T., Dickman R.T., Nilsson S., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Canc Inst 2002, 94:497-504.
311. Sit A.S., Modugno F., Weissfeld J.L., et al. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002, 86:118-123.
312. Miller J., Chan B.K., Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:680-690.
313. Hoffmann M., Hammar M., Kjellgren, et al. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005, 52:11-17.
314. Cassidenti D.L., Vijod A.G., Vijod M.A., et al. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1990, 163:1953.
315. Lobo R.A., Brenner P., Mishell D.R. Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement. Obstet Gynecol 1983, 62:94.
316. Lobo R.A. Clinical aspects of hormonal replacement-routes of administration. Treatment of Postmenopausal Women: Basic and Clinical Aspects 1999, 125-139. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. R.A. Lobo (Ed.).
317. Mashchak C.A., Lobo R.A., Dozono-Takano R., et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982, 144:511.
318. Stanczyk F.Z., Shoupe D., Nunez V., et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988, 159:1540.
319. Mandel F.P., Geola F.L., Meldrum D.R., et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983, 57:133.
320. Deutsch S., Ossowski R., Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981, 139:967.
321. Schmidt G., Anderson S.B., Nordle O., et al. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994, 38:253.
322. Lobo R.A. Progestogens. Menopause: Biology and Pathobiology 2000, 429-458. Academic Press, New York. R.A. Lobo, J. Kelsey, R. Marcus (Eds.).
323. Wollter-Sevensson L.-O., Stadberg E., Anderson K., et al. Intrauterine administration of levonorgestrel 5 and 10 mg/24 h in perimenopausal hormone replacement therapy: a randomized clinical trial during one year. Acta Obstet Gynecol Scand 1997, 76:449.
324. The Eye-Disease Case-Control Study Group Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992, 110:1701-1708.
325. Krall E.A., Dawson-Hughes B., Hannan M.T., et al. Postmenopausal estrogen replacement and tooth retention. Am J Med 1997, 102:536-542.
326. Civitelli R., Pilgram T.K., Dotson M. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy. Arch Intern Med 2002, 162:1409-1415.
327. Lobo R.A. Androgens in postmenopausal women: production, possible role and replacement options (CME Review Article). Obstet Gynecol Surv 2001, 56:361-376.
328. Bachmann G., Bancroft J., Braunstein G., et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002, 77:660-665.
329. Burger H.G., Hailes J., Menelaus M. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 1984, 6:351-358.
330. Shifren J.L., Braunstein G.D., Simon J.A. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000, 343:682-688.
331. Simon J., Braunstein G., Nachtigall L., et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005, 90(9):5226-5233.
332. Braunstein G.D., Sundwall D.A., Katz M., et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005, 165(14):1582-1589.
333. Kingsberg S., Shifren J., Wekselman E. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007, 4(4 Pt.1):1001-1008.
334. Lobo R.A., Rosen R.C., Yang H.-M., et al. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2002, 79:1341-1352.
335. Morales A.J., Nolan J.J., Nelson J.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994, 78:1360-1367.
336. Ross L.A., Alder E.M. Tibolone and climacteric symptoms. Maturitas 1995, 21:127-136.
337. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001, 86:5396-5404.
338. Lu L.J., Tice J.A., Bellino F.L. Phytoestrogens and healthy aging: gaps in knowledge (a workshop report). Menopause 2001, 8:157-170.
339. Erdman J.W. Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000, 102:2555-2559.
340. King R.J., Whitehead J.H. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986, 46:1062-1066.
341. Bradsher J.E., McKinlay S.M. Distinguishing the effects of age from those of menopause. Menopause: Biology and Pathobiology 2000, 203-211. Academic Press, New York. R.A. Lobo, J. Kelsey, R. Marcus (Eds.).
342. Iranmanesh A., Lizzaralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991, 73:1081.
343. Corpas E., Harman S.M., Pineyro M.A. Growth hormone (GH)-releasing hormone (I-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992, 75:530.
344. Khorram O., Laughlin G.A., Yen S.S.C. Endocrine and metabolic effects of long term administration of [Nle 27] growth hormone releasing hormone-(I-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997, 82:1472.
345. Ho K.Y., Evans W.S., Blizzard R.M. Effects of sex and age on the 24-hour profile of growth hormone in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987, 64:51.
346. Dawson-Hughes B., Stern D., Goldman J., Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiologic estrogen replacement. J Clin Endocrinol Metab 1986, 63:424.
347. Weissberger A.J., Ho K.K.Y., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein. J Clin Endocrinol Metab 1991, 72:374.
348. de Boer H., Blok G.-J., Vand der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995, 16:63.
349. Ghigo E., Arvat E., Giamotti L. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994, 78:693.
350. Chapman I.M., Bach M.A., Van Cauter E. Stimulation of the growth hormone (GH)/insulin-like growth factor-1 axis by daily oral administration of a GH secretagogue (MK-677) in health elderly subjects. J Clin Endocrinol Metab 1996, 81:4249.
351. Sowers M.F., Zheng H., Tomey K., et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007, 92(3):895-901.
352. Jurimae J., Jurimae T. Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 2007, 293(1):E42-47.
353. Chu M.C., Cosper P., Orio F., et al. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 2006, 194(1):100-104.
354. Casson P.R., Faquin L.C., Stentz F.B. Replacement of dehydroepiandrosterone (DHEA) enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995, 563:1027-1031.
355. Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986, 15:213-228.
356. Mellon S.H. Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab 1994, 78:1003.
357. Compagne N.A., Bulfone A., Rubenstein J.L.R., Mellon S.H. Steroidogenic enzyme p450c17 is expressed in the embryonic central nervous system. Endocrinology 1995, 136:5212.
358. Robel P., Baulieu E.-E. Neurosteroids: biosynthesis and function. Trends Endocrinol Metab 1994, 5:1.
359. Reus V.I., Wolkowitz O.W., Roberts E. Dehydroepiandrosterone (DHEA) and memory in depressed patients. Neuropsychopharmacology 1993, 9:665.
360. Wolkowitz O.M., Reus V.I., Roberts E. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann NY Acad Sci 1995, 774:337.
361. Van Cauter E., Leprooult R., Kupfer D.J. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996, 81:2468.
362. Blumel J.E., Prieto J.C., Leal T., et al. Cardiovascular risk factors in middle-age women with acute coronary syndromes. Rev Med Chil 2001, 129:995-1002.
363. Colditz G.A., Willett W.C., Stampfer M.J., et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987, 316:1105-1110.
364. Fioretti F., Tavani A., Gallus S., et al. Menopause and risk of non-fatal acute myocardial infarction: an Italian case-control study and a review of the literature. Hum Reprod 2000, 15:599-603.
365. Gordon T., Kannel W.B., Hjortland M.C., McNamara P.M. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med 1978, 89:157-161.
366. Manchester J.H., Herman M.V., Gorlin R. Premenopausal castration and documented coronary atherosclerosis. Am J Cardiol 1971, 28:33-37.
367. Parrish H.M., Carr C.A., Hall D.G., King T.M. Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967, 99:155-162.
368. Rosenberg L., Hennekens C.H., Rosner B., et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981, 139:47-51.
369. Rosenberg L., Miller D.R., Kaufman D.W., et al. Myocardial infarction in women under 50 years of age. JAMA 1983, 250:2801-2806.
370. Witteman J.C., Grobbee D.E., Kok F.J., et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989, 298:642-644.
371. Cooper G.S., Sandler D.P. Age at natural menopause and mortality. Ann Epidermiol 1998, 8:229-235.
372. de Kleijn M.J., van der Schouw Y.T., Verbeeck A.L., et al. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidermiol 2002, 155:339-345.
373. Fioretti F., Tavani A., Gallus S., et al. Menopause and risk of non-fatal acute myocardial infarction; an Italian case-control stuffy and a review of the literature. Hum Reprod 2000, 15:599-603.
374. Hu F.B., Grodstein F., Hennekens C.H., et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999, 156:1061-1066.
375. Jacobsen B.K., Knutsen S.F., Fraser G.E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidermiol 1999, 52:303-307.
376. Jacobsen B.K., Nissen S., Heuch I., Kvale G. Does age at natural menopause affect mortality from ischemic heart disease?. J Clin Epidermiol 1997, 50:475-479.
377. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: the Tromso Study. J Clin Epidermiol 53:525-530, 200.
378. Palmer J.R., Rosenberg L., Shapiro S. Reproductive factors and risk of myocardial infarction. Am J Epidermiol 1992, 136:408-416.
379. Parrish H.M., Carr C.A., Hall D.G., King T.M. Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967, 99:155-162.
380. Rosenberg L., Hennekens C.H., Rosner B., et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981, 139:47-51.
381. van der Schouw Y.T., van der Graaf Y., Steyerberg E.W., et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996, 347:714-718.
382. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006, 166:357-365.
383. Lobo R.A. Evidence-based medicine and the management of menopause. Clin Obstet Gynecol 2008, 51(3):534-538.
384. Treatment of the Postmenopausal Woman 2007, Academic Press, New York. 3rd ed. R.A. Lobo (Ed.).
385. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591-2602.
386. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308(5728):1583-1587.
387. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA 2007, 297(13):1465-1477.
388. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295(14):1647-1657.
389. Sowers M.F., Zheng H., Tomey K., et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007, 92(3):895-901.
390. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.